Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
J.R. Chalmers, E. Simpson, C.J. Apfelbacher, K.S. Thomas, L. von Kobyletzki, J. Schmitt, J.A. Singh, Å. Svensson, H.C. Williams, K. Abuabara, V. Aoki, M. Ardeleanu, M. Awici-Rasmussen, S. Barbarot, T.L. Berents, J. Block, A. Bragg, T. Burton, K.K. Bjerring Clemmensen, A. Creswell-Melville, M. Dinesen, A. Drucker, L. Eckert, C. Flohr, M. Garg, L.A.A. Gerbens, A.L.B. Graff, J. Hanifin, D. Heinl, R. Humphreys, H.A. Ishii, Y. Kataoka, Y.A. Leshem, B. Marquort, M.-A. Massuel, S. Merhand, H. Mizutani, H. Murota, D.F. Murrell, T. Nakahara, I. Nasr, K. Nograles, Y. Ohya, I. Osterloh, J. Pander, C. Prinsen, L. Purkins, M. Ridd, T. Sach, M.-L. A. Schuttelaar, S. Shindo, J. Smirnova, A. Sulzer, E. Synnøve Gjerde, R. Takaoka, H. Vestby Talmo, M. Tauber, F. Torchet, A. Volke, C.-F. Wahlgren, S. Weidinger, E. Weisshaar, A. Wollenberg, K. Yamaga, C.Y. Zhao and P.I. Spuls
Version of Record online: 19 JUL 2016 | DOI: 10.1111/bjd.14773
What's already known about this topic?
- Previous meetings of the Harmonising Outcome Measures for Eczema (HOME) initiative have achieved international consensus that the domains of clinician-reported signs, patient-reported symptoms, quality of life and long-term control should be measured as the core outcomes for atopic eczema clinical trials.
- It has been recommended that clinician-reported signs should be measured using the Eczema Area and Severity Index.
What does this study add?
- During the HOME IV meeting (Spring 2015, Malmö, Sweden), a consensus was achieved that the Patient-Oriented Eczema Measure should be used to capture patient-reported symptoms in future atopic eczema trials.
- The remaining two core outcome domains of quality of life and long-term control require further work to determine the preferred core outcome measurement instruments.